Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company has shown steady growth in its traditional Chinese and Western medicine business, with a revenue increase of 4.3% in the first nine months of 2024, accounting for 76.8% of total sales [1][2]. - The company reported a total revenue of 6.74 billion yuan for the first three quarters of 2024, reflecting a 3.6% year-on-year increase, while the net profit attributable to shareholders decreased by 63.8% to 100 million yuan [2][4]. - The company is expanding its store network through a combination of self-built and acquired stores, with a total of 5,501 stores as of Q3 2024, representing a 7.5% increase from the beginning of the year [2][3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 2.25 billion yuan, up 4.1% year-on-year, but the net profit attributable to shareholders fell by 68.5% to 40 million yuan [2]. - The projected net profits for 2024-2026 are estimated at 250 million yuan, 310 million yuan, and 360 million yuan respectively [1][4]. Business Expansion - The company is focusing on increasing the number and scale of stores in county-level and above markets, with 94.8% of its retail stores located in these areas [3]. - The company has a strategic plan to penetrate deeper into the market, particularly in cities with significant growth potential, while maintaining a strong presence in provincial capitals [3]. Revenue and Profitability Forecast - The company anticipates a revenue growth rate of 3% for retail business in 2024, with a projected compound annual growth rate of 30% for its professional services to pharmaceutical and convenience suppliers [6]. - The overall revenue forecast for 2024-2026 is expected to grow from 8.39 billion yuan in 2024 to 10.71 billion yuan in 2026, with a corresponding increase in gross margin [6][8].

证券代码：605266 证券简称：健之佳 公告编号：2024-099 健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司（以下简称"公司"） 于 2024 年 9 月 19 日召开第六届董事会第七次会议审议通过了《关于回购公司股份的方案》，同意公 司使用自有资金通过集中竞价交易方式回购公司部分股份，所回购股份将在披露 回购结果暨股份变动公告 12 个月后根据相关规则择机采用集中竞价交易方式出售。 本次回购金额不低于人民币 2,000 万元且不超过人民币 3,000 万元（均含本数）， 回购股份价格不超过人民币 29.80 元/股（含）。本次回购实施期限为自公司董事 会审议通过本次回购方案之日起不超过 3 个月。具体内容详见公司在上海证券交 易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案暨 回购报告书》（公告编号：2024-080）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购股份期间，上市公司应当每个月的前三个 交易日内，公告截至上月末的回购进展情况。现公司将截至 202 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-098 健之佳医药连锁集团股份有限公司 关于回购股份事项前十大股东及前十大无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、前十名股东持股情况 1 | 7 | 国泰基金管理有限公司－社保基金四二一 | 2,454,276 | 1.57 | | --- | --- | --- | --- | | | 组合 | | | | 8 | 中国建设银行股份有限公司－国泰大健康 | 2,218,272 | 1.42 | | | 股票型证券投资基金 | | | | 9 | 健之佳医药连锁集团股份有限公司－2024 | 2,051,152 | 1.31 | | | 年员工持股计划 | | | | 10 | 兴业银行股份有限公司－融通鑫新成长混 | 1,998,989 | 1.28 | | | 合型证券投资基金 | | | 注：以上股东的持股数量为合并普通账户和融资融券信用账户后的持股数量 总数。 | 序号 | 股东名称 | 持有数量 | 占公司无限 ...

关于 2024 年第三季度业绩说明会召开情况汇总 2024 年 10 月 30 日（星期三）上午 09:00-10:00，健之佳医药连锁集团 股份有限公司（以下简称"公司"）通过上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/）网络互动召开了 2024 年第三季度业绩说明 会，现将活动情况公告如下： 本次业绩说明会中投资者提出的问题及回复整理如下： 一、 请问贵公司是否考虑增持维护广大股东的利益？ 尊敬的投资者您好，感谢您对公司的关注。 公司重视股东的回报，坚持"稳定的收益、资产的增值是对股东的回报" 这一理念，长期专注核心主业，以合规经营、专业服务、业务转型应对市场、 政策、经营方面导致的行业重大变化。 业务合规安全基础上的稳健发展，是维护股东利益的长期基础和根本，以 此为基础应对资本市场、公司市值的波动。 公司建立了通过分红、回购等方式与股东分享经营成果、维护公司价值及 股东权益的规范机制。2024 年 6 月，公司员工持股计划以集中竞价交易方式 增持公司股份 5,000 万元。 2020 年 12 月公司上市后，3 个年度均通过较高比例现金分红维护股东利 益； ...

●回购股份的目的：维护公司价值及股东权益 ● 回购股份用途：本次回购的股份将按规范要求择机采用集中竞价交易方式 出售，并在披露回购结果暨股份变动公告后 3 年内完成出售。 ● 回购股份价格：不超过 31.69 元/股（含），该回购价格上限未超过董事 会审议通过本次回购股份方案决议前 30 个交易日公司股票交易均价的 150%。 证券代码：605266 证券简称：健之佳 公告编号：2024-096 健之佳医药连锁集团股份有限公司 关于以集中竞价方式回购股份的预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份方式：以集中竞价交易方式进行股份回购。 ● 回购股份期限：自董事会审议通过回购股份方案之日起不超过 3 个月。 ● 相关股东是否存在减持计划：经问询，截至董事会审议本次回购方案决议 之日，公司持股董监高、控股股东、实际控制人、回购提议人、持股 5%以上股东 在未来 3 个月、未来 6 个月暂无减持公司股份的计划。 若相关人员未来拟实施减持股份计划，将严格遵守相关法律法规的规定，履 行信息披露 ...

北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 终止实施 2024 年限制性股票激励计划暨 回购注销限制性股票相关事项的 关于健之佳医药连锁集团股份有限公司终止实施 2024 年 北京德恒（昆明）律师事务所 限制性股票激励计划暨回购注销限制性股票相关事项的法律意见 释 义 法律意见 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3-4 层 电话:0871-63172192 传真: 0871-63172192 邮编: 650032 | 释 义 | 1 | | --- | --- | | 正 文 | 1 | | 一、本次激励计划的实施情况 | 1 | | 二、本次终止及回购注销的批准与授权 | 2 | | 三、本次终止及回购注销的基本情况 | 2 | | 四、结论意见 | 3 | 本法律意见中，除非文中另有所指，下列简称具有如下特定含义： | 健之佳、公司 | 指 | 健之佳医药连锁集团股份有限公司 | | --- | --- | --- | | 本次激励计划 | 指 | 健之佳医药连锁集团股份有限公司2024年限 | | | | 制性股票激励计划 | | 本次终止及回购注销 | 指 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-092 健之佳医药连锁集团股份有限公司 第六届监事会第六次会议决议公告 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《2024 年第三季度报告》。 2、审议《关于公司对外投资设立职业技能培训学校的议案》 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 健之佳医药连锁集团股份有限公司（以下简称"公司"）第六届监事会第六 次会议通知于 2024 年 10 月 24 日以电子邮件方式通知全体监事，会议于 2024 年 10 月 29 日上午 10：30 以现场方式在云南省昆明市盘龙区联盟街道旗营街 10 号 健之佳总部 18 楼召开，应参加监事 3 人，实际参加监事 3 人，会议由监事会主 席金玉梅女士主持，符合《公司法》及《公司章程》等有关规定。 二、监事会会议审议情况 全体与会监事经认真审议和表决，形成以下决议： 1、审议《关于公司<2024 年第三季度报告>的议案》 议案表决情况：同意 3 票；反对 0 票 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-097 (一) 股东会类型和届次 2024 年第二次临时股东会 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 14 日 至 2024 年 11 月 14 日 健之佳医药连锁集团股份有限公司 关于召开 2024 年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东会召开日期：2024年11月14日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥2,250,082,059.03, representing a year-on-year increase of 4.08%[2]. - The net profit attributable to shareholders for Q3 2024 was ¥37,951,614.03, a significant decrease of 68.46% compared to the same period last year[2]. - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥31,138,725.05, down 73.06% year-on-year[2]. - The comprehensive gross profit margin decreased by 1.23 percentage points year-on-year, impacting the overall profitability[10]. - The gross profit margin for core business in Q3 2024 was 33.78%, down 1.58 percentage points from 35.36% in the same period last year[11]. - The total comprehensive income attributable to shareholders was approximately ¥100.69 million, down 63.84% from ¥278.44 million in the same quarter last year[20]. - The total profit for Q3 2024 was approximately ¥128.49 million, a decrease of 63.9% compared to ¥355.57 million in Q3 2023[66]. - Net profit attributable to shareholders of the parent company was approximately ¥100.83 million, down 63.8% from ¥278.44 million in the same period last year[66]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥10,706,011,092.22, reflecting a 7.61% increase from the end of the previous year[3]. - Total operating costs for the first three quarters of 2024 were ¥6,601,939,673.48, up from ¥6,135,379,989.31 in 2023, reflecting a year-on-year increase of 7.57%[65]. - The company's total liabilities reached ¥7,949,186,006.35, up from ¥7,104,318,260.69, which is an increase of 11.9%[64]. - Non-current liabilities increased to ¥2,405,358,983.54 from ¥2,244,206,002.82, reflecting a rise of 7.17%[64]. - The equity attributable to shareholders decreased to ¥2,775,798,827.19 from ¥2,861,130,202.55, a decline of 2.98%[64]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥502,088,314.28, showing a decline of 29.18% compared to the previous year[2]. - Cash flow from operating activities for the first nine months of 2024 was approximately ¥502.09 million, a decrease of 29.2% from ¥708.94 million in the same period of 2023[67]. - Cash inflow from operating activities totaled approximately ¥7.02 billion in the first nine months of 2024, compared to ¥6.94 billion in the same period of 2023[67]. - Cash outflow from investing activities was approximately ¥750.12 million in Q3 2024, compared to ¥671.79 million in Q3 2023[68]. - Cash received from financing activities increased by 276.07% to ¥1.26 billion, primarily due to loans for daily operations and acquisitions[21]. Market and Competition - The number of retail pharmacies in China reached 700,000 by mid-2024, indicating intensified competition in the industry[9]. - The forecast for the overall pharmaceutical market growth in 2024 is expected to decline to 4.9%, with retail pharmacy growth projected at only 2.9%[12]. - The company’s revenue in the Hebei region has been significantly impacted by policy restrictions, leading to a decline in operating income[34]. Strategic Initiatives - The company plans to slow down store expansion and focus on improving the operational efficiency of existing stores due to market and policy pressures[10]. - The company aims to adapt to external uncertainties by focusing on risk control and improving operational management efficiency[13]. - The company is focusing on reducing reliance on medical insurance by transitioning towards health products and professional services, aiming to enhance compliance and operational efficiency[57]. - The company has launched a comprehensive member management system to enhance customer loyalty and reduce churn rates through differentiated marketing services[46]. Growth and Development - The company has identified opportunities for growth among compliant and efficient retail enterprises in the face of industry challenges[12]. - The company is actively adapting to healthcare policy reforms and market trends, emphasizing a differentiated operational strategy to meet customer demands for high-quality health products[37]. - The company reported a year-to-date increase in operating revenue of 3.63%, which was lower than expected due to external pressures[10]. - The company is expanding cautiously into the southwestern region, specifically targeting the Guizhou market through acquisitions of retail chain companies[27]. Inventory and Expenses - Total inventory as of September 30, 2024, was ¥3,203,357,493.03, an increase of ¥829,793,346.55 or 34.96% due to a 16.77% growth in store numbers and increased stock for promotions[18]. - The company reported a significant increase in period expenses, which rose by 15.30% to RMB 778,760,864.44 compared to RMB 675,447,357.66 in the same period last year[11]. - Management expenses for Q3 2024 were ¥187,669,581.47, an increase of ¥51,547,488.20 or 37.87% driven by business scale growth and related costs[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,098, with no preferred shareholders having restored voting rights[22]. - The company initiated a share repurchase plan, with a total of 114,326 shares repurchased for RMB 29.98 million at a price range of RMB 21.56-29.99 per share[60]. - As of September 30, 2024, the company has repurchased an additional 10,900 shares for RMB 199.92 million at a price range of RMB 18.21-18.47 per share[61].

证券代码：605266 证券简称：健之佳 公告编号：2024-093 健之佳医药连锁集团股份有限公司 关于公司对外投资设立职业技能培训学校的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：健之佳职业技能培训学校昆明有限公司（以最后注册为 准） 投资金额：自有资金 100 万元 1 / 4 相关风险提示：全资子公司成立后在经营过程中可能面临宏观经济、行 业环境、市场变化等因素的影响，其未来经营情况存在一定的不确定性。 健之佳医药连锁集团股份有限公司（以下简称"公司"或"健之佳"）于 2024 年 10 月 29 日召开第六届董事会第八次会议，审议通过《关于公司对外投资设立 职业技能培训学校的议案》。现将具体内容进行公告： 一、投资概述 公司所处医药零售行业系面临医疗、药监、医保等方面高度监管、具有较高 合规要求的专业服务行业，其经营发展以合规、专业服务体系、运营管理体系为 基础，人员密集，人力资源系公司快速、稳健发展的核心推动因素。 公司推行"以人员管理为核心"的人才强企战略，长期坚持打造多维 ...